NASDAQ:DTIL Precision BioSciences Q3 2026 Earnings Date & Estimates $7.06 -0.38 (-5.11%) Closing price 10/30/2026 04:00 PM EasternExtended Trading$7.10 +0.04 (+0.57%) As of 10/30/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Precision BioSciences is scheduled to report Q3 2026 earnings on Tuesday, November 3, 2026, before market opens. The conference call is scheduled for 9:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 3, 2026TimeBefore Market OpensConference Call9:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Precision BioSciences in Q3 2026Precision BioSciences is expected to post earnings of -$0.85 per share on revenue of $1.38 million. In the same quarter a year earlier Precision BioSciences reported -$1.84 per share on revenue of $13 thousand. Precision BioSciences last reported on August 6, 2026, posting -$1.26 per share and missing the -$0.8040 consensus estimate. Precision BioSciences has beaten the consensus EPS estimate in 2 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.85Expected Revenue$1.38 millionPrior-Year EPS-$1.84Prior-Year Revenue$13 thousandExpected Revenue Growth+10,476.9%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$1.26 (Missed by -$0.4560)EPS Beat Rate2 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ3 2025 Earnings Report Precision BioSciences Q3 2026 Earnings FAQ When does Precision BioSciences report Q3 2026 earnings? Precision BioSciences (NASDAQ:DTIL) has confirmed it will report Q3 2026 earnings on Tuesday, November 3, 2026, before market opens. What time is Precision BioSciences' Q3 2026 earnings call? Precision BioSciences' Q3 2026 earnings conference call is scheduled for Tuesday, November 3, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Precision BioSciences? Analysts expect Precision BioSciences to post earnings of -$0.85 per share for Q3 2026. How much revenue is Precision BioSciences expected to report? The consensus revenue estimate for Precision BioSciences is $1.38 million for Q3 2026. Precision BioSciences Earnings HeadlinesAnalysts Are Bullish on Top Healthcare Stocks: Precision BioSciences (DTIL), ProKidney (PROK)October 30 at 5:36 AM | theglobeandmail.comPrecision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026October 29 at 9:30 AM | finance.yahoo.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.November 1 at 1:00 AM | Porter & Company (Ad)Precision BioSciences (NASDAQ:DTIL) Share Price Breaks Below Two Hundred Day Moving Average - What's Next?October 27, 2026 | americanbankingnews.comPrecision BioSciences (DTIL) Set to Post Earnings on MondayOctober 26, 2026 | americanbankingnews.comPrecision BioSciences Inc (DTIL)October 13, 2026 | in.investing.comSee More Precision BioSciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Precision BioSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Precision BioSciences and other key companies, straight to your email. Email Address About Precision BioSciencesPrecision BioSciences (NASDAQ:DTIL) is a biotechnology company developing gene-editing medicines using its proprietary ARCUS platform. ARCUS is based on engineered DNA-cutting enzymes designed to make targeted changes to genetic material, with the potential to remove, insert or correct DNA sequences in human cells. The company’s research and development activities have focused primarily on in vivo gene editing, in which therapeutic editing components are delivered directly into the body. Its development programs have included potential treatments for conditions such as chronic hepatitis B infection, Duchenne muscular dystrophy and certain rare genetic disorders. Precision BioSciences has also pursued collaborations and licensing arrangements to apply its gene-editing technology to additional therapeutic areas. Founded in 2006 and headquartered in Durham, North Carolina, Precision BioSciences became a publicly traded company in 2019. Its products remain in development, and the company’s operations are centered on biotechnology research, preclinical development and clinical-stage evaluation of gene-editing candidates for patients in the United States and international markets.View Precision BioSciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles LyondellBasell's Dividend Looks Safer, But a New Risk Could Change ThatEli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?Silicon Shock: Intel's 25% Valuation ResetMarketBeat Week in Review – 10/26 - 10/30DoorDash's $17 Billion Bet on Instacart Faces a Long Regulatory Road AheadAmazon's Record Margins Couldn't Stop the Sell-Off—Here's WhyStarbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch) Upcoming Earnings Marriott International (11/2/2026)Diamondback Energy (11/2/2026)Williams Companies (11/2/2026)Vertex Pharmaceuticals (11/2/2026)Realty Income (11/2/2026)Apple (11/2/2026)Palantir Technologies (11/2/2026)Entergy (11/2/2026)Booking (11/3/2026)Ferrari (11/3/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
